Venus Concept  logo
Venus Concept VERO

Quarterly report 2025-Q3
added 11-13-2025

report update icon

Venus Concept Financial Ratios 2011-2026 | VERO

Annual Financial Ratios Venus Concept

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.0 -0.0 -0.0 -4.0 -0.9 -1.5 -1.0 -8.6 - - - - - -

P/S

0.0 0.0 0.0 0.9 0.9 0.6 1.4 7.2 - - - - - -

EPS

-71.2 -68.5 -9.9 -0.4 -2.3 -4.8 -3.2 -2.4 -13.5 -14.7 - - - -

EV (Enterprise Value)

62.9 M 102 M 106 M 177 M 152 M 164 M 43.1 M 149 M 151 M 149 M - - - -

EBITDA per Share

-35.3 -44.5 -6.92 -0.18 -0.973 -3.28 -11.2 -8.66 - - - - - -

EV/EBITDA

-13.7 -3.2 -4.1 -1.3 -8.5 - - - - - -

PEG

-0.0 -0.0 -0.0 - -0.02 -0.02 0.03 -0.22 - - - - - -

P/B

0.6 -0.0 0.1 2.2 1.6 0.8 18.9 11.6 - - - - - -

P/CF

-0.2 -0.0 -0.0 -4.7 -2.4 -1.5 -1.0 -7.8 - - - - - -

ROE %

-1983.79 265.71 -539.97 -56.21 -184.72 -54.76 -1815.80 -135.23 - - - - - -

ROA %

-68.93 -39.77 -34.85 -14.62 -50.90 -21.25 -92.75 -54.12 - - - - - -

ROCE %

-72.63 -45.71 -40.96 -12.10 -31.60 -20.97 -119.97 -91.32 - - - - - -

Current Ratio

1.0 0.9 1.1 1.4 3.5 2.1 3.1 2.3 - - - - - -

DSO

181.0 220.6 228.4 243.2 263.7 195.0 109.2 66.2 - - - - - -

DIO

361.3 354.5 242.0 221.7 243.5 203.8 161.9 82.9 - - - - - -

DPO

138.0 128.8 89.6 85.3 86.7 101.7 111.8 61.4 - - - - - -

Operating Cycle

542.3 575.0 470.4 465.0 507.1 398.8 271.1 149.2 - - - - - -

Cash Conversion Cycle

404.3 446.2 380.9 379.6 420.5 297.1 159.2 87.8 - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Venus Concept

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-12.14 -8.03 -17.44 - -13.1 -30.93 -16.92 - -1.64 -1.35 -1.84 - -3.36 -2.47 -2.02 - -0.18 0.01 -0.17 - -0.18 -0.39 -1.68 - -1.77 -1.24 -1.1 -0.2 -3.03 -0.21 -0.26 -0.04 -4.07 -3.09 -3.2 -3.06 -3.67 -3.21 -3.61 - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-5.05 -6.14 -12.1 - -9.96 -8.5 -11.7 - -1.2 -1.01 -1.36 - -2.58 -1.59 -1.49 - -0.03 0.07 -0.1 - -0.04 -0.19 -1.42 - -1.3 -0.79 -0.32 - -2.65 -0.17 -0.24 - -2.76 -2.64 -0.26 - -3.21 - - - - - - - - - - - - - - - - - - - - - -

ROE %

-1981.80 -1224.99 -1178.47 -499.85 -426.26 -265.29 325.57 4872.50 4726.64 4507.18 4328.36 -216.78 -247.50 -132.35 -86.20 -55.45 -71.83 -57.48 -80.18 -151.52 -163.17 -158.44 -144.73 -26.72 -51.33 -486.52 -873.25 -1335.86 -1319.32 -922.47 -565.73 -135.23 -123.73 -69.61 -31.66 7.57 4.13 - - - - - - - - - - - - - - - - - - - - - -

ROA %

-87.53 -63.76 -70.19 -49.38 -58.43 -54.64 -36.60 -24.59 -36.70 -39.76 -40.73 -26.03 -32.43 -26.72 -18.51 -12.37 -16.88 -14.99 -21.22 -41.75 -46.27 -46.28 -43.40 -10.37 -16.75 -35.05 -52.12 -73.35 -70.20 -67.38 -62.41 -54.12 -76.18 -86.58 -71.39 -55.70 -30.40 - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-183.10 -108.75 -77.66 -40.85 -50.22 -43.63 -40.79 -28.11 -40.65 -43.81 -42.54 -25.83 -30.78 -23.18 -15.06 -9.35 -13.47 -12.65 -20.81 -44.90 -49.57 -50.12 -46.08 -8.81 -416.02 -818.55 -1142.80 -1179.27 -1214.18 -841.88 -548.52 -102.13 -98.42 -59.80 -26.11 3.71 3.71 - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.1 1.1 1.0 1.0 1.2 1.1 0.8 0.9 0.9 0.9 1.0 1.1 1.1 1.2 1.3 1.4 1.3 1.3 1.3 1.4 1.4 1.4 1.4 1.7 1.7 1.7 1.7 1.4 1.1 1.1 1.1 1.7 1.7 1.7 1.7 0.7 0.7 - - - - - - - - - - - - - - - - - - - - - -

DSO

160.7 139.4 166.6 - 185.4 185.3 191.2 - 230.7 224.1 234.3 - 274.0 237.4 247.6 - 251.8 239.0 276.8 - 309.7 376.8 500.6 - 310.6 292.0 293.2 517.5 124.4 109.5 95.1 60.2 84.4 60.9 52.9 43.7 30.8 - - - - - - - - - - - - - - - - - - - - - -

DIO

291.0 244.1 328.5 - 347.0 392.9 344.6 - 389.2 355.4 311.1 - 260.4 242.5 221.0 - 256.3 242.2 221.5 - 225.8 317.8 319.4 - 232.8 222.0 273.9 - 189.2 200.4 118.7 - 101.8 72.2 81.2 - 52.0 - - - - - - - - - - - - - - - - - - - - - -

DPO

119.2 96.3 129.3 - 128.4 144.4 131.6 - 129.5 123.2 103.8 - 57.4 49.8 51.2 - 65.6 75.9 77.2 - 80.4 113.1 137.2 - 68.8 59.5 56.1 - 133.0 138.5 83.9 - 75.4 53.5 55.9 - 33.0 - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

451.7 383.5 495.1 - 532.4 578.2 535.8 - 619.8 579.5 545.4 - 534.4 479.9 468.6 - 508.1 481.2 498.2 - 535.5 694.6 820.1 - 543.4 514.0 567.1 517.5 313.6 309.9 213.8 60.2 186.2 133.2 134.1 43.7 82.8 - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

332.5 287.1 365.7 - 404.1 433.8 404.1 - 490.4 456.4 441.6 - 477.0 430.1 417.4 - 442.6 405.3 421.0 - 455.1 581.5 682.9 - 474.6 454.5 511.0 517.5 180.6 171.4 129.8 60.2 110.9 79.7 78.3 43.7 49.8 - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Venus Concept , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.72 0.95 % $ 153 M usaUSA
AxoGen AxoGen
AXGN
$ 33.03 -4.08 % $ 1.52 B usaUSA
Butterfly Network Butterfly Network
BFLY
$ 4.07 -1.09 % $ 862 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 12.25 1.79 % $ 1.66 B usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 36.66 -0.27 % $ 5.46 K usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 62.57 -0.4 % $ 92.6 B usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 9.41 0.48 % $ 266 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 34.54 -0.72 % $ 1.07 B usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.62 5.64 % $ 38.6 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 9.76 1.35 % $ 350 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.5 3.24 % $ 131 M franceFrance
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 81.26 0.26 % $ 47.5 B usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
FONAR Corporation FONAR Corporation
FONR
$ 18.6 0.04 % $ 122 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Align Technology Align Technology
ALGN
$ 170.52 -0.05 % $ 12.8 B usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 1.87 0.27 % $ 1.14 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 9.31 -2.31 % $ 717 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Inogen Inogen
INGN
$ 6.42 3.38 % $ 171 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.99 1.47 % $ 16.8 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 96.6 0.38 % $ 1.23 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 85.01 -2.12 % $ 2.95 B usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 15.95 -0.68 % $ 374 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
LENSAR LENSAR
LNSR
$ 5.97 -1.49 % $ 71.4 M usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.38 3.38 % $ 56.1 M usaUSA
Medtronic PLC Medtronic PLC
MDT
$ 86.52 -0.13 % $ 111 B usaUSA
MiMedx Group MiMedx Group
MDXG
$ 3.89 -0.89 % $ 575 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Myomo Myomo
MYO
$ 0.69 3.22 % $ 28.9 M usaUSA